Click here for slides on this topic


Rosiglitazone

An oral antihyperglycemic agent of the thiazolidinedione class that is indicated as an adjunct to diet and exercise to improve glycemic control among adults with type 2 diabetes. Restricted use in the United States.
The following content matched the glossary term: Rosiglitazone

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

NDEI.org Expert Commentary on Type 2 Diabetes Treatment Trends from Vivian Fonseca, MD

Top

NDEI Education Council Member Vivian A. Fonseca, MD, comments on a study exploring type 2 diabetes treatment trends in the U.S.: “Clinicians could use these data to determine whether their own prescribing has changed in line with national trends”

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012

Top

Exclusive! Expert commentary from Vivian A. Fonseca, MD, on this study. Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care. 2014;37:985-992.

ADA 2016 Type 2 Diabetes Pharmacologic Therapy

Top

Pharmacologic treatment options for type 2 diabetes from the 2016 ADA guidelines

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

A clinical trial to maintain glycemic control in youth with type 2 diabetes

Top

TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. Epub ahead of print.The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study was a multicenter, randomized clinical trial that examined whether rosiglitazone plus metformin or intensive lifestyle intervention plus metformin initiated early in the disease course of youth-onset type 2 diabetes would maintain acceptable glycemic control better than metformin monotherapy.

ADA/European Association for the Study of Diabetes (EASD) Position Statement on Hyperglycemia Management in Type 2 Diabetes

Top

Joint position statement from ADA/EASD with clinical practice recommendations for managing hyperglycemia in type 2 diabetes

Clinical Insights in Diabetes Newsletter Archive

Top

Clinical Insights® in Diabetes Newsletter Archive

1 2 3 4 5 6 7 8 9 Next 

Slide Library Results

Search Results for: Rosiglitazone Slides Found: 47
Thiazolidinediones and Adipose Tissue Redistribution
Effect of Early Thiazolidinedione Therapy on A1C Levels
Effect of Early Thiazolidinedione Therapy on C-Peptide Levels
Effect of Early Thiazolidinedione Therapy on Diabetes Onset
Adverse Events Associated With Thiazolidinedione Treatment
GLAI: Enrollment Criteria
GLAI: Comparison of Pioglitazone vs Rosiglitazone on Glycemic Control
Vildagliptin Is as Effective as Rosiglitazone in Lowering A1C but Without Weight Gain in Drug-Naïve Patients With T2D
ADOPT: Cumulative Incidence of Monotherapy Failure at 5 Years
ADOPT: Adverse Events
ADOPT: Achievement of A1C Levels <7%
Thiazolidinediones vs Insulin: Comparison of Diabetes-Related Healthcare Utilization and Costs Over 12 Months
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Body Weight
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
Effect of Exenatide + TZD on Blood Glucose in Patients With Type 2 Diabetes
Effect of Exenatide + TZD on Body Weight in Patients With Type 2 Diabetes
RECORD: Study Design
RECORD: Effect of Rosiglitazone or Metformin Add-on to Sulfonylurea on A1C and FPG
RECORD: Effect of Rosiglitazone or Sulfonylurea Add-on to Metformin on A1C and FPG
Long-term Risk of Myocardial Infarction With Rosiglitazone: A Meta-analysis
Long-term Risk of Heart Failure With Rosiglitazone: A Meta-analysis
Long-term Risk of Cardiovascular Mortality With Rosiglitazone: A Meta-analysis
Duration of TZD Therapy Prior to Onset of Heart Failure
Dose and Duration of TZD Therapy Prior to Onset of Heart Failure
Pioglitazone Reduces the Risk of Hospitalization for AMI
GLAI: Comparison of TZDs on Lipoprotein Subclass Particle Size
Effect of Sitagliptin vs Rosiglitazone When Added to Metformin Monotherapy
RECORD: Study Design
RECORD: CV Death and Hospitalization
RECORD: Time to Primary Endpoint
RECORD: Bone Fracture Rates in Upper and Distal Lower Limbs
RECORD: Conclusion
Risk of Cardiovascular Events During Treatment with Pioglitazone or Rosiglitazone: Design
Risk of Cardiovascular Events During Treatment with Pioglitazone or Rosiglitazone: Composite Outcome
CANOE: Low-Dose Combination Therapy With Rosiglitazone Plus Metformin for Diabetes Prevention
CANOE: Development of New-Onset Diabetes With Low-Dose Combination Therapy Vs Placebo
TODAY Study: Design
TODAY Study: Eligibility Criteria and Run-in Period
TODAY Study: Baseline Characteristics
TODAY Study: Primary Outcome—Loss of Glycemic Control
Liraglutide Reduces A1C Irrespective of Baseline A1C
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on A1
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on Body
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on Fasting
Rosiglitazone Cardiovascular Risk RECORD Slides | NDEI
RECORD Rosiglitazone Cardiovascular Effects Slides | NDEI
GLP-1 Receptor Agonists A1C Type 2 Diabetes | NDEI